Sigilon Therapeutics Inc. (SGTX)
NASDAQ: SGTX
· Real-Time Price · USD
22.47
-0.59 (-2.56%)
At close: Aug 10, 2023, 8:00 PM
-2.56% (1D)
| Bid | n/a |
| Market Cap | 56.22M |
| Revenue (ttm) | 17.65M |
| Net Income (ttm) | -29.57M |
| EPS (ttm) | -14.83 |
| PE Ratio (ttm) | -1.5151719487525288 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 81,878 |
| Avg. Volume (20D) | 120,683 |
| Open | 22.90 |
| Previous Close | 23.06 |
| Day's Range | 22.09 - 23.08 |
| 52-Week Range | 3.77 - 28.00 |
| Beta | 4.11 |
About SGTX
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged rel...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 62
Stock Exchange NASDAQ
Ticker Symbol SGTX
Website https://www.sigilon.com